BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q3 EPS of ($0.38), $0.08 worse than the analyst estimate of ($0.30). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE